What are the appropriate alternatives to tadalafil for an adult with erectile dysfunction or pulmonary arterial hypertension, including dosing, contraindications, and cost considerations?

Therapeutic Substitution for Tadalafil

Direct Answer

For pulmonary arterial hypertension (PAH), sildenafil 20 mg three times daily is the most appropriate therapeutic substitute for tadalafil, with dose escalation to 80 mg three times daily if clinical response is inadequate 1, 2. For erectile dysfunction, sildenafil or vardenafil are appropriate alternatives, with most patients preferring tadalafil when given the choice 3.

---

Substitution for Pulmonary Arterial Hypertension

First-Line PDE5 Inhibitor Alternative

Sildenafil is the primary therapeutic substitute for tadalafil in PAH, offering the same mechanism of action with robust evidence for efficacy 1, 2.

Dosing regimen:

• Start at 20 mg orally three times daily, spaced 4-6 hours apart 2
• If inadequate clinical response after adequate trial, escalate by 20 mg increments to maximum 80 mg three times daily 1, 2
• Clinical trials demonstrate dose-response relationship for hemodynamic parameters up to 80 mg three times daily 2

Evidence for sildenafil:

• Grade 1C recommendation to improve 6-minute walk distance (6MWD) in WHO functional class II-III patients 1, 2
• Improves WHO functional class 1
• Reduces mean pulmonary arterial pressure and pulmonary vascular resistance 2
• Most common adverse effects are headache and dyspepsia 2

Key advantage over tadalafil: No routine laboratory monitoring required, unlike endothelin receptor antagonists 2.

Key disadvantage: Three-times-daily dosing versus tadalafil's once-daily regimen may reduce compliance 1.

Alternative Oral Agents (Non-PDE5 Inhibitors)

If PDE5 inhibitors are contraindicated or not tolerated, endothelin receptor antagonists (ERAs) or riociguat are appropriate alternatives 1.

Ambrisentan:

• Start 5 mg daily, increase to 10 mg daily if tolerated and treatment goals not reached 1
• Grade 1C recommendation to improve 6MWD 1
• Once-daily dosing improves compliance 1
• Requires monthly pregnancy testing in women of childbearing age 1
• Check hemoglobin and liver function tests every 1-3 months 1

Macitentan:

• 10 mg once daily 1
• Improves WHO functional class and delays time to clinical worsening 1
• Teratogenic; requires monthly pregnancy testing 1
• Lower incidence of fluid retention compared to other ERAs 1

Bosentan:

• Start 62.5 mg twice daily for 4 weeks, then increase to 125 mg twice daily 1
• Grade 1B recommendation to improve 6MWD 1
• Requires monthly liver function test monitoring due to higher transaminase elevation risk 1
• Twice-daily dosing and monitoring requirements make it less preferable than ambrisentan or macitentan 1

Riociguat (soluble guanylate cyclase stimulator):

• Requires dose titration 1
• Improves 6MWD, WHO functional class, delays time to clinical worsening 1
• Absolutely contraindicated with any PDE5 inhibitor due to severe systemic hypotension risk 1, 2, 4
• Three-times-daily dosing reduces compliance 1
• Excluded patients with baseline systolic blood pressure <95 mmHg in pivotal trials 1

Combination Therapy Considerations

If patient was on tadalafil monotherapy with inadequate response, consider adding a second class of PAH therapy rather than simple substitution 1:

• Ambrisentan plus sildenafil can be used as combination therapy 1
• Adding inhaled treprostinil to sildenafil improved 6MWD by 20 meters in WHO FC III patients (Grade 2C) 2
• Adding sildenafil to stable IV epoprostenol increased 6MWD by 29 meters 2

Critical contraindication: Never combine riociguat with any PDE5 inhibitor 1, 2, 4.

Switching Protocol from Tadalafil to Sildenafil

Based on clinical experience in PAH patients, overnight switching is safe and effective 5:

• Discontinue tadalafil after evening dose
• Initiate sildenafil 20 mg three times daily the next morning 5
• 97% of patients successfully transitioned without clinical deterioration 5
• 6MWD remained unchanged after transition 5
• Minimal adverse events: headache (4%), heartburn (2%) 5

Monitoring after switch:

• Re-evaluate at 2-3 months using 6MWD, WHO functional class, and symptom review 2
• Monitor for clinical worsening (death, lung transplantation, PAH-related hospitalization, need for additional therapy) 2

Parenteral Options for Severe Disease

For WHO functional class III patients with rapid progression or poor prognostic markers (right ventricular failure, 6MWD <380 meters, right atrial pressure >20 mmHg, cardiac index <2.0 L/min/m²), consider continuous IV epoprostenol or IV/subcutaneous treprostinil instead of oral agent substitution 1, 2.

For WHO functional class IV patients, initial parenteral prostanoid therapy is advised rather than oral substitution 1, 4.

---

Substitution for Erectile Dysfunction

PDE5 Inhibitor Alternatives

Sildenafil or vardenafil are appropriate substitutes for tadalafil in erectile dysfunction 3, 6.

Sildenafil:

• Typical dosing: 25-100 mg as needed, 30-60 minutes before sexual activity 3
• Well-tolerated with similar adverse effect profile to tadalafil 3
• Shorter duration of action (4-6 hours) versus tadalafil (up to 36 hours) 7

Patient preference data: In a European multicenter trial, 90.5% of men previously taking sildenafil elected to continue with tadalafil over sildenafil after crossover trial 3. This preference was consistent across age groups, ED severity, and etiology 3.

Key consideration: Tadalafil offers once-daily dosing option (2.5-5 mg daily) that decouples dosing from sexual activity, which may explain patient preference 7.

Contraindications Common to All PDE5 Inhibitors

Absolute contraindications:

• Concomitant nitrate use (risk of life-threatening hypotension) 2, 4
• Concomitant riociguat use (severe systemic hypotension) 1, 2, 4

Relative contraindications:

• Baseline systolic blood pressure <100 mmHg 1
• Protease inhibitor use (strong CYP3A4 inhibition) 1

---

Cost Considerations

No comparative cost data provided in guidelines, but practical considerations include 1:

• Insurance formulary coverage varies by agent
• Generic sildenafil availability may reduce cost compared to branded tadalafil
• Monthly monitoring requirements for ERAs (liver function tests, pregnancy tests) add indirect costs 1
• Three-times-daily sildenafil dosing may reduce compliance compared to once-daily tadalafil, potentially increasing long-term costs through treatment failure 1

---

Common Pitfalls and How to Avoid Them

Do not combine riociguat with any PDE5 inhibitor - this is an absolute contraindication due to severe hypotension risk 1, 2, 4.

Do not use PDE5 inhibitors with nitrates - absolute contraindication due to life-threatening hypotension 2, 4.

Counsel male PAH patients not to use additional PDE5 inhibitors for erectile dysfunction while on sildenafil or tadalafil for PAH 1.

Expect less pronounced response in PAH associated with systemic sclerosis compared to idiopathic PAH 1, 2.

Do not empirically substitute without assessing adequacy of prior tadalafil trial - ensure patient received adequate duration and dose before declaring treatment failure 1.

Monitor compliance carefully when switching from once-daily tadalafil to three-times-daily sildenafil - dosing frequency significantly impacts adherence 1.